Abstract
Pancreatic cancer (PC) is the fourth leading cause of cancer related deaths in the U.S., with a less than 6% fiveyear survival rate. Treatment is confounded by advanced stage of disease at presentation, frequent metastasis to distant organs at the time of diagnosis and resistance to conventional chemotherapy. In addition, the molecular pathogenesis of the disease is unclear. The extensive study of miRNAs over the past several years has revealed that miRNAs are frequently de-regulated in pancreatic cancer and contribute to the pathogenesis and aggressiveness of the disease. Several studies have tackled the practical difficulties in the application of miRNAs as viable therapeutic and diagnostic tools. Given that a single miRNA can affect a myriad of cellular processes, successful targeting of miRNAs as therapeutic agents could likely yield dramatic results. The current review attempts to summarize the advances in the field and assesses the prospects for miRNA profiling and targeting in aiding PC treatment.
Keywords: MiRNA, therapy, pancreatic cancer.
Current Drug Targets
Title:Prospects of miRNA-Based Therapy for Pancreatic Cancer
Volume: 14 Issue: 10
Author(s): Priya Pai, Satyanarayana Rachagani, Chandrakanth Are and Surinder K. Batra
Affiliation:
Keywords: MiRNA, therapy, pancreatic cancer.
Abstract: Pancreatic cancer (PC) is the fourth leading cause of cancer related deaths in the U.S., with a less than 6% fiveyear survival rate. Treatment is confounded by advanced stage of disease at presentation, frequent metastasis to distant organs at the time of diagnosis and resistance to conventional chemotherapy. In addition, the molecular pathogenesis of the disease is unclear. The extensive study of miRNAs over the past several years has revealed that miRNAs are frequently de-regulated in pancreatic cancer and contribute to the pathogenesis and aggressiveness of the disease. Several studies have tackled the practical difficulties in the application of miRNAs as viable therapeutic and diagnostic tools. Given that a single miRNA can affect a myriad of cellular processes, successful targeting of miRNAs as therapeutic agents could likely yield dramatic results. The current review attempts to summarize the advances in the field and assesses the prospects for miRNA profiling and targeting in aiding PC treatment.
Export Options
About this article
Cite this article as:
Pai Priya, Rachagani Satyanarayana, Are Chandrakanth and Batra K. Surinder, Prospects of miRNA-Based Therapy for Pancreatic Cancer, Current Drug Targets 2013; 14 (10) . https://dx.doi.org/10.2174/13894501113149990181
DOI https://dx.doi.org/10.2174/13894501113149990181 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Hypoxia-Inducible Factor: A Potential Therapeutic Target for Rheumatoid Arthritis
Current Drug Targets Bio-Distribution, Imaging Protocols and Diagnostic Accuracy of PET with Tracers of Lipogenesis in Imaging Prostate Cancer: a Comparison between 11C-Choline, 18FFluoroethylcholine and 18F-Methylcholine
Current Pharmaceutical Design Nuclear Imaging of Inflammation in Neurologic and Psychiatric Disorders
Current Clinical Pharmacology Targeting Transient Receptor Potential Channels in Cardiometabolic Diseases and Myocardial Ischemia Reperfusion Injury
Current Drug Targets The Design of Amphiphilic Polymeric Micelles of Curcumin for Cancer Management
Current Medicinal Chemistry CDKN2B-AS1: An Indispensable Long Non-coding RNA in Multiple Diseases
Current Pharmaceutical Design Stable Expression of the Sodium/Iodide Symporter (NIS) for anti-Cancer Gene Therapy of Glioma Cells Using a Third Generation Self-Inactivating Lentiviral Vector System in Combination with 211At
Current Radiopharmaceuticals Peptides for Tumour Therapy and Diagnosis: Current Status and Future Directions
Current Medicinal Chemistry Epigenetic Changes Induced by Green Tea Catechins a re Associated with Prostate Cancer
Current Molecular Medicine Recent Patents on Mesenchymal Stem Cell Mediated Therapy in Inflammatory Diseases
Recent Patents on Inflammation & Allergy Drug Discovery Ultrasound-Triggered Immunotherapy for Cancer Treatment: An Update
Current Protein & Peptide Science mTOR Inhibitors in Tuberous Sclerosis Complex
Current Neuropharmacology The 18 kDa Translocator Protein (TSPO): A New Perspective in Mitochondrial Biology
Current Molecular Medicine Mode of Action of Long-Term Low-Dose Macrolide Therapy for Chronic Sinusitis in the Light of Neutrophil Recruitment
Current Drug Targets - Inflammation & Allergy Levetiracetam might act as an efficacious drug to attenuate cognitive deficits of Alzheimer’s disease
Current Topics in Medicinal Chemistry Recent Patents Reveal Microtubules as Persistent Promising Target for Novel Drug Development for Cancers
Recent Patents on Anti-Infective Drug Discovery Calpain-Associated Proteolytic Regulation of the Stromal Microenvironment in Cancer
Current Pharmaceutical Design C-Myc Signaling Pathway in Treatment and Prevention of Brain Tumors
Current Cancer Drug Targets Metabolism and the Paradoxical Effects of Arsenic: Carcinogenesis and Anticancer
Current Medicinal Chemistry Tumor-related Molecular Regulatory Mechanisms of Long Non-coding RNA RMST: Recent Evidence
Mini-Reviews in Medicinal Chemistry